Key Highlights

  • Humana (NYSE:HUM) closed up 11.56% on October 9, 2026, with intraday gains of 12% to 14% shown elsewhere, after CMS restored a 4-star rating to its flagship Medicare Advantage contract, according to published market data.
  • The flagship contract, numbered H5216, covers over 2 million members, and more than 90% of Humana (NYSE:HUM) members are in plans rated 4 stars or higher for 2027, though one summary quoted 95%.
  • Barclays raised its price target to USD 582 and Baird to USD 596, as reported, which are analyst opinions and not forecasts, while shares of Humana (NYSE:HUM) trade above USD 400 and are up about 76% year to date.
  • Open enrollment starts October 15, 2026, so the improved ratings arrive just as Humana (NYSE:HUM) competes for members, with UnitedHealth reporting Earnings on October 13 and the Fed meeting following on October 27 and 28.

Why One Contract Rating Moves a Whole Stock

Star ratings drive Medicare Advantage economics. Plans rated 4 stars or higher earn quality Bonus payments, and they receive a larger share of rebates that fund richer benefits such as lower premiums and extra coverage. A single large contract matters because Humana (NYSE:HUM) concentrates a large share of its Business in Medicare Advantage. With H5216 covering more than 2 million members, restoring its 4-star rating changes Revenue expectations for the 2027 plan year. The company filing and CMS release are the confirming documents, while the share of members in 4-star plans has been quoted as over 90% in one summary and 95% in another, so the exact number should be rechecked before it is relied on.

Reading the Price Reaction

The close of 11.56% is the verified figure, while intraday gains of 12% to 14% appear in other published data. A rise of this size in a stock priced above USD 400 adds tens of dollars per share in one session. The shares are up about 76% year to date, so much of the good news may already be reflected, and a stock at a 52-week high can fall back if earnings do not match expectations. Humana (NYSE:HUM) also benefits from the contrast with rivals. Alignment Healthcare (NASDAQ:ALHC) fell about 13% on the same release. Price targets of USD 582 from Barclays and USD 596 from Baird are as reported and are single-day analyst views.

Risks After the Rally

Ratings are reassessed each year, so a 4-star rating is not permanent, and a decline in a later cycle would reverse the benefit. Medical costs in Medicare Advantage have pressured insurers in recent periods, and higher use of care can erode margins even with strong ratings. Open enrollment begins October 15, when benefit design and Marketing spend determine how many members Humana (NYSE:HUM) keeps or wins. Policy changes at CMS, including payment rate decisions, can also change Economics regardless of ratings. Investors will watch UnitedHealth's results on October 13 for industry read-across, since the largest insurer sets the tone for utilization trends and for the pricing of 2027 plans.

Where Things Stand

Humana (NYSE:HUM) surged about 12% because CMS restored a 4-star rating to its flagship Medicare Advantage contract, which supports bonus payments and richer 2027 benefits for more than 2 million members. The closing gain was 11.56%, and the move came after a year in which the shares had already risen about 76%. The catalyst is verified, though price targets and the 95% versus over 90% member share are reported figures. The next tests are UnitedHealth's results on October 13, open enrollment from October 15 and cost trends. None of this guarantees further gains.